Analysts expect Vitamin Shoppe Inc (NYSE:VSI) to report earnings per share of $0.08 for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Vitamin Shoppe’s earnings. The highest EPS estimate is $0.16 and the lowest is $0.02. Vitamin Shoppe reported earnings of $0.37 per share in the same quarter last year, which would indicate a negative year over year growth rate of 78.4%. The business is expected to announce its next earnings results on Wednesday, May 9th.
According to Zacks, analysts expect that Vitamin Shoppe will report full year earnings of ($0.19) per share for the current financial year, with EPS estimates ranging from ($0.33) to ($0.06). For the next financial year, analysts forecast that the firm will report earnings of ($0.25) per share, with EPS estimates ranging from ($0.59) to $0.00. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Vitamin Shoppe.
Vitamin Shoppe (NYSE:VSI) last announced its quarterly earnings results on Tuesday, February 27th. The specialty retailer reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.03. Vitamin Shoppe had a negative net margin of 21.39% and a positive return on equity of 3.13%. The firm had revenue of $268.77 million during the quarter, compared to analyst estimates of $269.24 million. During the same period in the previous year, the business posted $0.36 earnings per share. The business’s revenue for the quarter was down 11.8% on a year-over-year basis.
A number of brokerages have recently commented on VSI. Zacks Investment Research upgraded shares of Vitamin Shoppe from a “strong sell” rating to a “hold” rating in a research note on Sunday, January 21st. ValuEngine lowered shares of Vitamin Shoppe from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Finally, Morgan Stanley reduced their price target on shares of Vitamin Shoppe from $4.00 to $3.75 and set an “equal weight” rating for the company in a research note on Wednesday, February 28th. Four equities research analysts have rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $4.95.
In other Vitamin Shoppe news, major shareholder Shah Capital Management bought 300,000 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The stock was bought at an average cost of $3.83 per share, for a total transaction of $1,149,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Vintage Capital Management Llc purchased 234,343 shares of the stock in a transaction on Friday, December 29th. The shares were purchased at an average cost of $4.36 per share, for a total transaction of $1,021,735.48. The disclosure for this purchase can be found here. Insiders have purchased 1,000,639 shares of company stock valued at $4,387,647 over the last 90 days. 1.07% of the stock is currently owned by company insiders.
A number of large investors have recently modified their holdings of the business. Pinebridge Investments L.P. lifted its holdings in Vitamin Shoppe by 28.3% during the fourth quarter. Pinebridge Investments L.P. now owns 63,860 shares of the specialty retailer’s stock valued at $281,000 after purchasing an additional 14,079 shares in the last quarter. Crossmark Global Holdings Inc. lifted its holdings in Vitamin Shoppe by 122.8% during the fourth quarter. Crossmark Global Holdings Inc. now owns 31,320 shares of the specialty retailer’s stock valued at $138,000 after purchasing an additional 17,260 shares in the last quarter. Macquarie Group Ltd. purchased a new position in Vitamin Shoppe during the third quarter valued at approximately $101,000. Lazard Asset Management LLC purchased a new position in Vitamin Shoppe during the fourth quarter valued at approximately $115,000. Finally, KBC Group NV lifted its holdings in Vitamin Shoppe by 46.7% during the third quarter. KBC Group NV now owns 107,786 shares of the specialty retailer’s stock valued at $577,000 after purchasing an additional 34,301 shares in the last quarter. 89.03% of the stock is currently owned by institutional investors and hedge funds.
Shares of Vitamin Shoppe (NYSE VSI) opened at $4.35 on Friday. Vitamin Shoppe has a 12 month low of $2.95 and a 12 month high of $20.70. The company has a market cap of $112.54, a P/E ratio of 11.63 and a beta of 0.64. The company has a quick ratio of 0.36, a current ratio of 2.25 and a debt-to-equity ratio of 0.65.
COPYRIGHT VIOLATION NOTICE: “$0.08 Earnings Per Share Expected for Vitamin Shoppe Inc (VSI) This Quarter” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://ledgergazette.com/2018/03/20/0-08-earnings-per-share-expected-for-vitamin-shoppe-inc-vsi-this-quarter.html.
Vitamin Shoppe Company Profile
Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vitamin Shoppe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe and related companies with MarketBeat.com's FREE daily email newsletter.